Thus, methylation changes could be a possible molecular marker for HNSCC risk/prognosis, since the methylation of the GALR gene promoter has been related to HNSCC carcinogenesis [193], and GAL1R/GAL2R hypermethylation has been associated with higher recurrence rates and reduced disease-free survival [194,200]. The gene discussed is GALR2; the disease is head and neck squamous cell carcinoma.